Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor epidermal growth factor receptor (EGFR) mutations

BACKGROUND: Patients with stage IV lung adenocarcinoma and EGFR mutation derive clinical benefit from treatment with EGFR tyrosine kinase inhibitors (TKI). Whether treatment with TKI improves outcomes in patients with resected lung adenocarcinoma and EGFR mutation is unknown. METHODS: Data were anal...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Janjigian, Yelena Y., Park, Bernard J., Zakowski, Maureen F., Ladanyi, Marc, Pao, William, D’Angelo, Sandra P., Kris, Mark G., Shen, Ronglai, Zheng, Junting, Azzoli, Christopher G.
Formato: Artigo
Idioma:Inglês
Publicado: 2011
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3778680/
https://ncbi.nlm.nih.gov/pubmed/21150674
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e318202bffe
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares